rss2
4DMT
4DMT | Powering The Future Of Genetic Medicines · 4dmoleculartherapeutics.com · American English
4D Molecular Therapeutics designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions.
rss2 wordpress content atom dc sy
https://4dmoleculartherapeutics.com/feed/
- Last post
- Sep 11, 2026
- Posts in 24 h · 7 days · 30 days
- 0 · 0 · 1
- Our last check
- Answering
- Served from
- United States
- Site title
- 4DMT | Powering The Future Of Genetic Medicines
- Text score at discovery
- 329
- Format
- rss2
- Features in the feed
- content, atom, dc, sy
- Community
- wordpress
Posts
What our queue read from this feed. Open one to read it here, or go to the site that published it.
- A Strategic Shift for Gene Therapies: Manufacturing and Market Size Take Centre Stage
Sep 11, 2026 · original
August 24, 2026 | Pharmaceutical Technology The post A Strategic Shift for Gene Therapies: Manufacturing and Market Size Take Centre Stage first appeared on 4DMT . - 4DMT Targets Global Retina Market with Long-lasting Genetic Treatment
Aug 12, 2026 · original
June 17, 2026 | RBC Capital Markets The post 4DMT Targets Global Retina Market with Long-lasting Genetic Treatment first appeared on 4DMT . - 4D-150 Gene Therapy Reduces Treatment Burden in Wet AMD
Aug 12, 2026 · original
August 11, 2026 | Healio The post 4D-150 Gene Therapy Reduces Treatment Burden in Wet AMD first appeared on 4DMT . - 4DMT’s 2-year PRISM Data Show Durable Treatment Burden Reduction with 4D-150 in Wet AMD
Aug 12, 2026 · original
July 23, 2026 | Ophthalmology Times The post 4DMT’s 2-year PRISM Data Show Durable Treatment Burden Reduction with 4D-150 in Wet AMD first appeared on 4DMT . - ASRS 2026: 4D-150 Gene Therapy Shows Sustained Treatment-burden Reduction in Wet AMD at 2 years
Aug 12, 2026 · original
July 22, 2026 | Modern Retina The post ASRS 2026: 4D-150 Gene Therapy Shows Sustained Treatment-burden Reduction in Wet AMD at 2 years first appeared on 4DMT . - Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration
Aug 12, 2026 · original
July 20, 2026 | MedPage Today The post Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration first appeared on 4DMT . - 4DMT Completes Enrollment in 4FRONT-2, Global Phase 3 Trial of 4D-150 in Wet AMD
Aug 12, 2026 · original
June 30, 2026 | Ophthalmology Times The post 4DMT Completes Enrollment in 4FRONT-2, Global Phase 3 Trial of 4D-150 in Wet AMD first appeared on 4DMT . - 4DMT Completes Enrollment in Second Phase 3 Trial of 4D-150 for Wet AMD
Aug 12, 2026 · original
June 29, 2026 | Eyewire News The post 4DMT Completes Enrollment in Second Phase 3 Trial of 4D-150 for Wet AMD first appeared on 4DMT . - The Onyx Life Sciences Report: Companies we’re watching in 2026
Apr 1, 2026 · original
February/March Edition | Fortune The post The Onyx Life Sciences Report: Companies we’re watching in 2026 first appeared on 4DMT . - Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Apr 1, 2026 · original
February 6, 2026 | Scrip The post Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation first appeared on 4DMT .
Discovered by the rss-feed-index crawler, which checks each feed at most once a month.
Same record as JSON: https://api.agentalog.com/api/feeds/fd_4dmoleculartherapeutics_com_02ffa488529dcf64. More from this site: 4dmoleculartherapeutics.com in the Feeds tab.